These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9161907)

  • 1. Biocompatibility in cardiopulmonary bypass.
    Hsu LC
    J Cardiothorac Vasc Anesth; 1997 May; 11(3):376-82. PubMed ID: 9161907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized, masked clinical trial.
    Muehrcke DD; McCarthy PM; Kottke-Marchant K; Harasaki H; Pierre-Yared J; Borsh JA; Ogella DA; Cosgrove DM
    J Thorac Cardiovasc Surg; 1996 Aug; 112(2):472-83. PubMed ID: 8751516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin-coated circuits reduce complement activation and inflammatory response to cardiopulmonary bypass.
    Tamim M; Demircin M; Guvener M; Peker O; Yilmaz M
    Panminerva Med; 1999 Sep; 41(3):193-8. PubMed ID: 10568115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of allogenic red cell transfusion and coated bypass circuit on the inflammatory response during cardiopulmonary bypass: a randomized study.
    Senay S; Toraman F; Gunaydin S; Kilercik M; Karabulut H; Alhan C
    Interact Cardiovasc Thorac Surg; 2009 Jan; 8(1):93-9. PubMed ID: 18801802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin-coated circuits reduce the formation of TNF alpha during cardiopulmonary bypass.
    Yamada H; Kudoh I; Hirose Y; Toyoshima M; Abe H; Kurahashi K
    Acta Anaesthesiol Scand; 1996 Mar; 40(3):311-7. PubMed ID: 8721461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin-coated cardiopulmonary bypass circuits: current status.
    Hsu LC
    Perfusion; 2001 Sep; 16(5):417-28. PubMed ID: 11565897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiopulmonary bypass circuit treated with surface-modifying additives: a clinical evaluation of blood compatibility.
    Gu YJ; Boonstra PW; Rijnsburger AA; Haan J; van Oeveren W
    Ann Thorac Surg; 1998 May; 65(5):1342-7. PubMed ID: 9594864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomaterial development for cardiopulmonary bypass.
    Gourlay T
    Perfusion; 2001 Sep; 16(5):381-90. PubMed ID: 11565893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. eComment: Re: The impact of allogenic red cell transfusion and coated bypass circuit on the inflammatory response during cardiopulmonary bypass: a randomized study.
    Bockeria LA; Grigoryants RG
    Interact Cardiovasc Thorac Surg; 2009 Jan; 8(1):99. PubMed ID: 19122158
    [No Abstract]   [Full Text] [Related]  

  • 10. Deleterious effects of cardiopulmonary bypass on early graft function after single lung allotransplantation: evaluation of a heparin-coated bypass circuit.
    Francalancia NA; Aeba R; Yousem SA; Griffith BP; Marrone GC
    J Heart Lung Transplant; 1994; 13(3):498-507. PubMed ID: 8061027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inflammatory response and haematological disorders in cardiac surgery: toward a more physiological cardiopulmonary bypass].
    Baufreton C; Corbeau JJ; Pinaud F
    Ann Fr Anesth Reanim; 2006 May; 25(5):510-20. PubMed ID: 16488106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin-coated bypass circuits: effects on inflammatory response in pediatric cardiac operations.
    Schreurs HH; Wijers MJ; Gu YJ; van Oeveren W; van Domburg RT; de Boer JH; Bogers AJ
    Ann Thorac Surg; 1998 Jul; 66(1):166-71. PubMed ID: 9692458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of Duraflo II heparin-treated extracorporeal circuits on the systemic inflammatory response in patients having coronary bypass.
    Weerwind PW; Maessen JG; van Tits LJ; Stad RK; Fransen EJ; de Jong DS; Penn OC
    J Thorac Cardiovasc Surg; 1995 Dec; 110(6):1633-41. PubMed ID: 8523873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Issues of biocompatibility: heparin-coated extracorporeal circuit.
    Hsu LC
    Int Anesthesiol Clin; 1996; 34(2):109-22. PubMed ID: 8799749
    [No Abstract]   [Full Text] [Related]  

  • 15. Extracorporeal circulation, hemocompatibility, and biomaterials.
    Janvier G; Baquey C; Roth C; Benillan N; Bélisle S; Hardy JF
    Ann Thorac Surg; 1996 Dec; 62(6):1926-34. PubMed ID: 8957436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass.
    Steinberg BM; Grossi EA; Schwartz DS; McLoughlin DE; Aguinaga M; Bizekis C; Greenwald J; Flisser A; Spencer FC; Galloway AC
    Ann Thorac Surg; 1995 Sep; 60(3):525-9. PubMed ID: 7677475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiopulmonary bypass technology transfer: musings of a cardiac surgeon.
    Rubens FD
    J Biomater Sci Polym Ed; 2002; 13(4):485-99. PubMed ID: 12160305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete heparin-coated (CBAS) cardiopulmonary bypass and reduced systemic heparin dose; effects on coagulation and fibrinolysis.
    Ovrum E; Brosstad F; Am Holen E; Tangen G; Abdelnoor M; Oystese R
    Eur J Cardiothorac Surg; 1996; 10(6):449-55. PubMed ID: 8817142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Release of lipopolysaccharide toxicity-modulating proteins in patients undergoing cardiopulmonary bypass using noncoated and heparin-coated extracorporeal circuits. A clinical pilot study.
    Bouma M; Maessen J; Weerwind P; Dentener M; Fransen E; de Jong D; Buurman W
    Chest; 1997 Mar; 111(3):577-83. PubMed ID: 9118690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin-coated cardiopulmonary bypass circuits.
    Gravlee GP
    J Cardiothorac Vasc Anesth; 1994 Apr; 8(2):213-22. PubMed ID: 8204814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.